Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineeringKathryn Michels, Shon Green, Anai M. Perez et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 108
Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an <i>In Vivo</i> Anti-CD19 CAR T Cell TherapyAlissa Brandes, Ryan Larson, A. Koo et al.|Blood|2024Cited by 5
438 In vivo Engineered CAR-T cells for oncology using a surface-engineered lentivirus platform: nonclinical safety and biodistributionAlissa Brandes, Ryan Larson, Soo Min Koo et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1